胃粘膜病变核仁组成区嗜银蛋白的银染计量和能谱分析

对77例胃粘膜活检标本进行银染,显示核仁组成区相关的嗜银蛋白(Ag-NOR),进行计数和统计分析,并对银染标本作电镜观察及能谱分析。结果表明,Ag-NOR 颗粒计数的多少,对胃肿瘤恶性程度的诊断有重要参考价值。电镜证实银染物质定位于核仁组成区,银染阳性区能谱分析显示 Ag 峰,说明银染反应具特异性.     

核仁组成区蛋白在软组织肿瘤及瘤样病变中的表达与意义

应用胶银技术,对软组织肿瘤特别是纤维源性肿瘤核仁组成区蛋白进行了定量研究。在软组织一些恶性肿瘤中,以血管肉瘤、横纹肌肉瘤核仁组成区蛋白均值最高,并以此排列了它们的恶性度顺序。在纤维源性肿瘤中,纤维瘤、瘤样纤维组织增生、纤维肉瘤及其亚类核仁组成区蛋白均值有显著与高度显著性差异(P<0.05、P<0.001),其中随访的34例纤维肉瘤患者,具有高核仁组成区蛋白均值(≥5)与低核仁组成区蛋白均值(<5)的5年生存率分别是20％和53％(P<0.05)。因此,作者认为核仁组成区蛋白定量在判定软组织肿瘤的恶性度、鉴别其良恶性及预测患者预后中均有一定实用价值。     

人增殖细胞核抗原的表达调控

增殖细胞核抗原(proliferating cell nuclear antigen,PCNA)是一种生长调控蛋白,在DNA复制、修复、细胞周期调控、基因外遗传(epigenetic inheritance)等事件的协同机制中发挥重要功能。PCNA的表达调控发生在多个层次,涉及ATFl、CREB、RFXl、p53、E2F等转录因子以及内含子指导的反义RNA等等。     

增殖细胞核抗原在低氧大鼠肺动脉平滑肌细胞中表达

目的通过建立低氧性肺动脉高压大鼠模型,探讨增殖细胞核抗原(proliferating cell nuclear antigen,PCNA)在大鼠低氧性肺血管平滑肌细胞中的表达。方法将SPF级SD大鼠随机分为正常对照组(n=10)、模型组(n=10),通过间断常压低氧法建立大鼠低氧性肺动脉高压模型,肺组织切片经HE染色后图像分析技术定量检测大鼠肺小动脉的形态改变;免疫组织化学染色法测定肺血管平滑肌细胞内PCNA蛋白表达,并经图像分析半定量检测其表达强度。结果 4周后,模型组SD大鼠MT%、MA%与对照组比较,差异具有显著性(P<0.05);模型组SD大鼠肺血管平滑肌细胞内PCNA核蛋白表达(积分面积、累积光密度)与对照组比较,差异具有显著性(P<0.05)。结论常压低氧4周可成功建立肺动脉高压大鼠模型,PCNA在肺血管平滑肌细胞中的表达量具有差异性提示其可能在肺动脉高压形成过程中起重要作用。     

用ribozyme抑制增殖细胞核抗原的表达对HeLa细胞增殖的影响

增殖细胞核抗的（ＰＣＮＡ）是ＤＮＡ聚合酶δ的辅助蛋白,它是细胞染色体ＤＮＡ复制所必需的。人工设计的ｒｉｂｏｚｙｍｅ具有可特异地切割ＰＣＮＡｍＲＮＡ的性质,将此ｒｉｂｏｚｙｍｅ的自剪体内表达质粒导入ＨｅＬａ细胞,从细胞决ＲＮＡ中分离相应部分能在体外切割靶ＲＮＡ片段,证明此表达质粒在细胞内能表达出有活性的ｒｉｂｏｚｙｍｅ分子。与对照相比,导入ｒｉｂｏｚｙｍｅ表达质粒的ＨｅＬａ细胞进入Ｓ期的时间从１２ｈ     

甲状腺良、恶性病变中增殖细胞核抗原、P_(53)蛋白与AgNOR的检测及相关性研究

本文应用ＬＳＡＢ免疫组织化学方法及ＡｇＮＯＲ技术对７３例甲状腺良、恶性病变ＰＣ－ＮＡ、Ｐ５３蛋白及ＡｇＮＯＲ进行了检测并对其相关性进行了研究。结果显示①ＰＣＮＡ表达在良、恶性病变中有显著差异（Ｐ＜０．０１）;②ＡｇＮＯＲ颗粒均数及其形态在良、恶性病变中有较显著差异;③ＰＣＮＡ表达与ＡｇＮＯＲ计数呈显著正相关性（Ｐ＜０．０１）;④Ｐ５３蛋白在良、恶性病变中的表达均呈阴性,只是在淋巴结转移灶内呈阳性表达。根据研究我们认为检测甲状腺良、恶性病变中ＰＣＮＡ及ＡｇＮＯＲ颗粒对甲状腺良、恶性病变的鉴别、预后及对临床治疗均有意义     

增殖细胞核抗原在小鼠肾小体发育中的表达

目的研究小鼠肾小体发生发育过程中增殖细胞核抗原(PCNA)的表达水平.方法采用免疫组织化学方法结合光学显微镜技术.结果比较发育不同阶段肾小体PCNA表达时,处于原始阶段,即Ⅰ期和Ⅱ期肾小体内PCNA阳性率最高;而随着肾小体生长发育和成熟,即Ⅲ、Ⅳ、Ⅴ期肾小体,PCNA的表达会逐渐减弱.在比较不同胚龄及生后日龄的同期肾小体时发现,Ⅰ期、Ⅱ期肾小体内PCNA阳性细胞率不因胚(日)龄的增加而变化;而Ⅲ期、Ⅳ期和Ⅴ期随着胚龄的增加,特别是生后日龄的增加阳性率逐渐下降.结论细胞增殖在肾小体发育的整个过程中是由高逐渐减低.生后龄肾内生长阶段肾小体的PCNA阳性率明显低于胚龄时生长阶段肾小体.     

用ribozyme抑制增殖细胞核抗原的表达对HaLa细胞增殖的影响

增殖细胞核抗原(PCNA)是DNA聚合酶δ的辅助蛋白,它是细胞染色体DNA复制所必需的。人工设计的ribozyme具有可特异地切割PCNA mRNA的性质,将此ribozyme的自修剪体内表达质粒导入HeLa细胞,从细胞总RNA中分离相应部分能在体外切割靶RNA片段,证明此表达质粒在细胞内能表达出有活性的ribozyme分子。与对照相比,导入ribo-zyme表达质粒的HeLa细胞进入S期的时间从12 h推迟到20 h,而突变ribozyme的对照表明反义抑制对细胞进入S期的影响较小(推迟到15 h)。证明该ribozyme能有效抑制He-La细胞DNA复制,同时亦证明PCNA对于细胞DNA复制及细胞周期进程的重要性。     

增殖细胞核抗原蛋白在Spodoptera frugiperda昆虫细胞中的表达及纯化

目的:利用昆虫细胞表达系统生产重组的人增殖细胞核抗原(proliferating cell nuclear antigen,PCNA),并进行纯化和抗体结合特性鉴定。方法:以HeLa细胞逆转录的cDNA为模板,扩增人PCNA基因,并插入杆状病毒载体AcMNPV。利用昆虫细胞得到PCNA基因的重组杆状病毒。病毒感染细胞表达蛋白,联合镍柱亲和层析和离子交换层析获得高纯度的重组人PCNA蛋白。ELISA法测定抗体结合特异性。结果:以HeLa细胞cDNA为模板得到的基因序列同GenBank的人PCNA基因序列一致。草地贪夜蛾细胞(Spodoptera frugiperda,Sf9)表达重组人PCNA(recombinant human PCNA,rPCNA)的最佳感染值(MOI)和感染时间分别为0.05h和144h。rPCNA的产量高达110mg/L细胞,纯度95%。间接ELISA法检测抗体结合特性,rPCNA的敏感性和特异性分别为93.3%和85.0%。结论:建立了rPCNA的表达和纯化方法,获得了高效表达、高度抗体结合特异性的PCNA蛋白,该蛋白质能进一步开发为PCNA相关疾病的体外诊断试剂盒,具较大的应用价值。     

小鼠睾丸表皮生长因子受体及增殖细胞核抗原表达的加龄变化研究

观察了表皮生长因子受体及增殖细胞核抗原在生后１天至生后１０月龄昆明种小鼠睾丸内的表达,结果表明：精原细胞及初级精线产细胞从生后第２周至生后４周龄ＤＮＡ复制旺盛,增殖细胞核抗原免疫反应阳性细胞面密度于生后１４天出现峰值。生长因子受体在间质细胞、精母细胞内均有表达。生后４周时,精母细胞表皮生长因子受体表达较强,便于表皮生长因子发挥调节细胞增殖、调亡的作用。     

VEGF和PCNA在骨肉瘤组织中的表达及其临床意义

目的:探讨血管内皮生长因子(VEGF)和增殖细胞核抗原(PCNA)在骨肉瘤组织中的表达及其与微血管密度(MVD)、预后的关系。方法:用免疫组织化学法检测64例骨肉瘤组织中VEGF、PCNA的表达和MVD。结果:VEGF阳性表达主要在胞浆,PCNA的阳性表达主要在胞核。VEGF、PCNA表达与MVD存在显著关联(P<0.05),与骨肉瘤转移和5年生存率有显著关联性(P<0.05)。VEGF表达与PCNA表达密切相关(P<0.05)。结论:VEGF和PCNA指标可作为判断骨肉瘤预后的重要指标。     

Autoantibodies recognizing proteins copurified with PCNA in patients with connective tissue diseases

Objective. Proliferating cell nuclear antigen (PCNA), one of the target antigen recognized by lupus sera, has been reported to be present as a subnuclear multi-peptide complex. But autoantibodies reacting with components of PCNA complex are poorly understood. To study the specificity of those autoantibodies, immunoreactivities of autoimmune sera against purified PCNA antigen were studied. Methods. PCNA antigens were purified from rabbit thymus extract by affinity column using murine monoclonal antibodies (mAbs) to PCNA, TOB7, TO17 and TO30. Immunoreactivities of autoimmune sera against purified PCNA were analyzed by WB. Results. PCNA antigen purified by serum AK predominantly showed a 34 kD band specific for PCNA in SDS-PAGE. When antigens were purified by anti-PCNA mAb TOB7 and TO30 which are known to be targeting different epitopes on PCNA antigen, SDS-PAGE analysis showed various mol. wt of proteins in addition to the 34 kD PCNA while both AK and mAbs reacted only with 34 kD PCNA in WB. In WB using PCNA purified by TOB7, various immunoreactivities were observed at 150, 66, 58, 48, 45, 37, 32 and 16 kDa in sera from patients with connective tissue diseases. Conclusions. These results suggested that many of the proteins copurified with PCNA were also targets of autoimmune responses and these autoantibody experssion may be induced through antigen-driven mechanisms.Abbreviations mAb monoclonal antibody - PCNA proliferating cell nuclear antigen - PCNA/AK PCNA affinity purified by antibodies from patient serum AK - PCNA/TO30 PCNA purfied by mAb TO30 - PCNA/TOB7 PCNA purified by mAb TOB7 - SLE systemic lupus erythematosus     

PCNA、P27蛋白在老年胃癌中的表达及其临床意义

目的：探讨增殖细胞核抗原（PCNA）和P27蛋白（P27）在老年胃癌中表达及其临床意义。方法：采用免疫组织化学SP法检测58例老年胃癌组织中PCNA、P27蛋白表达情况,分析它们与老年胃癌临床生物学行为的关系。结果：PCNA在老年胃癌组中的阳性表达率明显高于对照组的阳性表达率,P27在老年胃癌组中的阳性表达率明显低于对照组的阳性表达率。PCNA蛋白阳性表达与老年胃癌是否有浆膜浸润、组织分化程度、淋巴结转移以及TNM分期密切相关（P〈0.01）,而P27蛋白阳性表达与老年胃癌类型、是否有浆膜浸润、组织分化程度、淋巴结转移以及TNM分期密切相关（P〈0.01）。老年胃癌组织中PCNA、P27的表达呈负相关（r=-0.536,P〈0.05）。结论：P27表达下调、PCNA表达增强在老年胃癌的发生、发展过程中具有重要的作用,且两者具有相互作用。     

Expression of p120, Ki-67 and PCNA as proliferation biomarkers in imprint smears of prostate carcinoma and their prognostic value

The cell proliferation markers p120, Ki-67 and proliferating cell nuclear antigen (PCNA) recognize nuclear antigens. The expression of these proteins by immunostaining methods was reported to be of value in determining the prognosis of patients with malignant diseases. In this study, we evaluated the prognostic significance of the expression of nuclear antigens p120, PCNA and Ki-67 in prostate cancer and compared the results with other prognostic factors. Imprint smear samples obtained from 70 patients immediately after radical prostatectomy for prostatic carcinoma were immunostained with monoclonal antibodies against p120, Ki-67 and PCNA. The immunostaining results were correlated with Gleason score, tumour differentiation, stage and prostatic specific antigen (PSA) levels. Our findings demonstrate that p120, Ki-67 and PCNA expression in prostatic carcinoma smears, correlated significantly with the degree of Gleason score (P < 0.001). When combining p120, Ki-67 and PCNA positivity with tumour differentiation there was a significant association among these parameters (P < 0.001). Overexpression of p120, Ki-67 and PCNA, was also associated with increased PSA serum levels (>4 ng/ml) (P < 0.001). The distribution of p120, Ki-67 and PCNA expression in prostate carcinomas was not statistically significant for Ki-67 (P = 0.69) and p120 (P = 0.22) but was significant for PCNA (P < 0.001) as far as the histological stage (T2a, T2b, T2c, T3a). P120, Ki-67 and PCNA expression had significant prognostic value for disease-free survival. Our results conclude that nuclear antigens p120, Ki-67 and PCNA appear to be additional markers in the field of prognosis of prostatic carcinoma.     

Arsenic Inhibits DNA Mismatch Repair by Promoting EGFR Expression and PCNA Phosphorylation

Both genotoxic and non-genotoxic chemicals can act as carcinogens. However, while genotoxic compounds lead directly to mutations that promote unregulated cell growth, the mechanism by which non-genotoxic carcinogens lead to cellular transformation is poorly understood. Using a model non-genotoxic carcinogen, arsenic, we show here that exposure to arsenic inhibits mismatch repair (MMR) in human cells, possibly through its ability to stimulate epidermal growth factor receptor (EGFR)-dependent tyrosine phosphorylation of proliferating cellular nuclear antigen (PCNA). HeLa cells exposed to exogenous arsenic demonstrate a dose- and time-dependent increase in the levels of EGFR and tyrosine 211-phosphorylated PCNA. Cell extracts derived from arsenic-treated HeLa cells are defective in MMR, and unphosphorylated recombinant PCNA restores normal MMR activity to these extracts. These results suggest a model in which arsenic induces expression of EGFR, which in turn phosphorylates PCNA, and phosphorylated PCNA then inhibits MMR, leading to increased susceptibility to carcinogenesis. This study suggests a putative novel mechanism of action for arsenic and other non-genotoxic carcinogens.     

Conversion from mitosis to meiosis: morphology and expression of proliferating cell nuclear antigen (PCNA) and Dmc1 during newt spermatogenesis

The conversion from mitosis to meiosis is a phenomenon specific to the cellular progenitors of gametes; however, the mechanism or mechanisms responsible for this conversion are poorly understood. To this end, some morphological and molecular changes that occur during the initiation of meiosis in newt spermatogenesis are reported in the present paper. In situ morphologic studies revealed that spermatogonial stages comprise two phases: early mitotic generations (G1-G4) and late mitotic generations (G5-G8). Morphologic conversion from secondary spermatogonia to primary spermatocytes occurred during the intermediate stage of premeiotic DNA replication. The expression of proliferating cell nuclear antigen (PCNA), a DNA polymerase-delta auxiliary protein, in spermatogonia was weak in G1, highest during DNA synthesis (S), decreased in G2 and was not detectable in dividing cells. Complementary DNA for newt homologs of DMC1 (disrupted meiotic cDNA), which is an Escherichia coli RecA-like protein specifically active during meiosis, were isolated. The newt Dmc1 mRNA was first expressed significantly during the preleptotene stage and this continued into the spermatid stage. These observations present a basis for investigating the mechanism(s) controlling the conversion of newt spermatogonial cells from mitosis to meiosis.     

靶向增殖细胞核抗原shRNA的构建及其对HepG2细胞增殖与凋亡的影响

为了探讨抑制增殖细胞核抗原(PCNA)基因表达对人肝癌HepG2细胞增殖及凋亡的影响,将前期筛选出的最佳siRNA序列转化为能表达其小发夹结构RNA(smallhairpinRNAs,shRNA)的DNA序列,并与pSilencer2.0-U6质粒定向连接,构建靶向PCNA基因的siRNA真核表达载体pShPCNA,经DNA测序证实与设计完全一致.随后采用WST法及克隆形成抑制观察细胞增殖抑制情况、划痕实验来观察细胞迁移能力,流式细胞术、Hoechest33258染色、细胞线粒体膜电位改变检测细胞凋亡.在转染HepG2细胞48h后,pShPCNA组细胞PCNAmRNA表达明显下调,并出现明显的增殖抑制作用,明显抑制细胞克隆的形成和细胞的迁移力,且呈剂量-效应关系.流式细胞术检测发现:pShPCNA组细胞明显阻滞于G0/G1期,并出现明显的亚二倍体凋亡峰,出现明显的早期凋亡细胞群.荧光显微镜检测表明,细胞线粒体膜电位降低,并且细胞出现核固缩、凋亡小体等凋亡形态学变化.上述结果表明,成功构建了靶向PCNA基因的siRNA真核表达载体pShPCNA,pShPCNA转染HepG2细胞48h后,能够显著抑制细胞的生长增...